Log in to save to my catalogue

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomi...

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_500469

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

About this item

Full title

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Publisher

England: Elsevier Ltd

Journal title

Lancet neurology, 2017-02, Vol.16 (2), p.123-134

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Neurofibrillary pathology composed of tau protein is a main correlate of cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting pathological tau proteins is therefore a promising strategy for disease-modifying treatment of Alzheimer's disease. We have developed an active vaccine, AADvac1, against patho...

Alternative Titles

Full title

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_swepub_ki_se_500469

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_500469

Other Identifiers

ISSN

1474-4422

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(16)30331-3

How to access this item